In the era of digital health transformation, generative AI (GenAI) has emerged as a breakthrough technology in pharmacovigilance, the science dedicated to ensuring drug safety.
A pair of artificial intelligence algorithms from Boston Scientific and Medtronic can be used by the NHS to monitor heart failure patients with implantable devices, but two others from Biot
UK digital health company RHYTHM AI has claimed FDA approval for a new version of its algorithm for mapping areas of the heart that are affected by atrial fibrillation (AFib) that will be r
Chemists at ETH Zurich have developed a new computer process that enables the generation of active pharmaceutical ingredients at speed, based on a protein’s three-dimensio
UK researchers say they have developed an algorithm that is more accurate than current tools at predicting an individual’s risk of developing cardiovascular disease in the
The FDA has cleared an artificial intelligence algorithm that can detect signs of heart failure in seconds using a digital stethoscope during a standard physical exam.
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and developments that have occurred since inaugural discussions last year